

KING & SPALDING

King & Spalding LLP
1700 Pennsylvania Avenue, N.W.
Washington, DC 20006-4706
www.kslaw.com

Theodore M. Hester
Partner
Direct Dial: (202) 626-2901
thester@kslaw.com

June 8, 2012

BY HAND DELIVERY

The Honorable Max Baucus, Chairman
The Honorable Charles E. Grassley
Committee on Finance
United States Senate
Washington, D.C. 20510

Dear Senators Baucus and Grassley:

This letter is submitted on behalf of Purdue Pharma L.P. (or "Purdue") in response to your May 8, 2012 letter to John H. Stewart requesting information on Purdue's relationship with certain non-profit health care organizations and professionals. Pursuant to our discussions with your staff, we are submitting this letter and the enclosed DVD in response to Request 1), and will continue to produce responsive material on a rolling basis to the remaining requests.

The DVD Purdue is providing with this letter contains and constitutes confidential and proprietary information that is being provided pursuant to Rule XXIX of the Standing Rules of the Senate. Purdue respectfully requests that your staff members and anyone else reviewing this confidential information on your behalf employ appropriate safeguards to protect against its disclosure and to limit access outside of formal Senate proceedings. Purdue also respectfully requests advance notice of any contemplated disclosure of its confidential information, and a reasonable opportunity to object. Please direct any such notice to me at the above address.

Purdue supports professional organizations and leading medical experts who have educated, and continue to educate, health care professionals, patients, and caregivers about appropriate clinical practices in the area of pain management. According to a recent report by the Institute of Medicine, approximately 100 million Americans suffer from chronic pain, much of which has gone untreated or undertreated.¹ Purdue's efforts to foster appropriate pain

¹ Committee on Advancing Pain Research, Care, and Education, Institute of Medicine, *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research* 1 (2011), available at <http://www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx>.

management through educational materials and support for health care professionals and organizations are designed to ensure that patients with chronic pain benefit from a full range of therapeutic treatment options. The monies expended by Purdue set forth in its response to Request 1) comprise a broad array of activities from clinical research (totaling \$1.6 million) to non-promotional medical education programs and materials for healthcare professionals, patients and caregivers (totaling \$8.0 million).

In addition to its support of appropriate pain management, Purdue makes substantial investments in efforts focused on addressing the abuse, misuse, and diversion of opioid medications. In fact, from 2001 to date, Purdue has contributed more than \$40 million to anti-abuse and anti-diversion initiatives, including public service ads, collaboration with law enforcement, provision of tamper-resistant prescription pads, support for monitoring and tracking programs, and community-based partnerships and drug abuse awareness and education programs. These voluntary efforts closely mirror, even though they long pre-date, the categories of goals and recommendations for action set forth in the Prescription Drug Abuse Prevention Plan promulgated in 2011 by the White House Office of National Drug Control Policy (ONDCP): (1) Education; (2) Tracking and Monitoring; (3) Proper Medication Disposal; and (4) Enforcement.² The materials in the enclosed brochure set forth descriptions of some of the more significant programs.

The representations herein are based on Purdue's current information and belief and its understanding of the terms used in your May 8 letter. In responding to your requests, Purdue does not waive, nor does it intend to waive, any of its rights or privileges with respect to this inquiry by the Committee, including any applicable attorney-client, work product, or other evidentiary privilege, or any objection to the letter request from the Committee.

If you or any member of your staff has any questions regarding this response, please do not hesitate to call me at (202) 626-2901.

Sincerely,

A handwritten signature in black ink, appearing to read 'T. Hester', written over the word 'Sincerely,'.

Theodore M. Hester

Enclosures

² See White House Office of National Drug Control Policy, *Epidemic: Responding to America's Drug Abuse Crisis* (2011), available at http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdf.